C4 Therapeutics, Inc.
C4 Therapeutics, Inc.（CCCC）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · CCCC · 截至 2025年9月30日
股东结构概览
103
机构持有人数
▼ 1 vs Q2
$116.64M
机构持仓总市值
▲ $38.39M vs Q2
82.83M
总流通股
freeFloat 84.86%
52.54M
13F 申报持股数
▼ 2.18M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
CCCC 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
LYNX1 CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 7.10M | 10.00% | 10.00% | $15.76B | Nov 13, 2025 | — held |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 7.05M | 9.93% | 9.93% | $15.66B | Nov 14, 2025 | ▲ 75.0K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 5.24M | 7.37% | 7.37% | $11.62B | Nov 14, 2025 | ▼ 1.60M |
MORGAN STANLEY biological products, (no diagnostic substances) | 4.97M | 7.00% | 7.00% | $11.04B | May 27, 2026 | ▲ 217.8K |
WASATCH ADVISORS LP biological products, (no diagnostic substances) | 4.85M | 6.83% | 6.83% | $10.77B | Nov 14, 2025 | ▼ 2.57M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.19M | 4.49% | 4.49% | $7.09B | Nov 7, 2025 | ▲ 173.5K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 2.05M | 2.89% | 2.89% | $4.56B | Feb 3, 2026 | ▲ 45.2K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 1.93M | 2.72% | 2.72% | $4.29B | Nov 14, 2025 | ▲ 832.9K |
SILVERARC CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.90M | 2.67% | 2.67% | $4.21B | Nov 12, 2025 | ▲ 1.90M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.60M | 2.25% | 2.25% | $3.54B | Nov 12, 2025 | ▼ 233.0K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
18
增持
+4.55M 股8
新建仓
首次建仓17
减持
−5.75M 股0
清仓
完全退出净股数变化（前50家）
1.20M
+4.55M / −5.75M
净新增持仓人
+9
新建 8 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
CCCC 内幕交易记录
数据来源：SEC Form 4
2
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Anderson Kenneth Carl director | Apr 1, 2026 | Award | 4,259 | $2.70 | $11.5K | 68.2K | Form 4 ↗ |
GROGAN DONNA ROY director | Apr 1, 2026 | Award | 5,370 | $2.70 | $14.5K | 71.5K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 13, 2026 | Award | 200,000 | — | — | 307.8K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 13, 2026 | Tax Withhold | 1,735 | $1.89 | $3.3K | 306.1K | Form 4 ↗ |
Boyle Scott N Chief Business Officer | Feb 14, 2026 | Tax Withhold | 7,269 | $1.89 | $13.7K | 298.8K | Form 4 ↗ |
Mahaney Paige Chief Scientific Officer | Feb 13, 2026 | Award | 240,000 | — | — | 339.4K | Form 4 ↗ |
Mahaney Paige Chief Scientific Officer | Feb 14, 2026 | Tax Withhold | 2,446 | $1.89 | $4.6K | 336.9K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 13, 2026 | Award | 200,000 | — | — | 308.9K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 13, 2026 | Tax Withhold | 1,735 | $1.89 | $3.3K | 307.1K | Form 4 ↗ |
Schick Kelly Chief People Officer | Feb 14, 2026 | Tax Withhold | 7,269 | $1.89 | $13.7K | 299.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
C4 Therapeutics, Inc.（CCCC）主要由机构投资者持有，机构持股比例约为 63.4%。公司内部人员持股约 15.14%，散户及公众持股约占剩余的 21.42%。
C4 Therapeutics, Inc. 最大机构股东为 LYNX1 CAPITAL MANAGEMENT LP，截至 September 30, 2025 持有约 7.10 million 股，占总流通股的 10.00%。
目前共有 103 家机构持有 CCCC 股票，合计持仓市值约 $116,636,299，数据来源为最新 SEC 13F 申报。
常见问题
CCCC ownershipC4 Therapeutics, Inc.（CCCC）主要由机构投资者持有，机构持股约 63.4%。最大股东为 LYNX1 CAPITAL MANAGEMENT LP，持股比例 10.00%。内部人员持股约 15.14%。数据来源 SEC Form 13F，截至 September 30, 2025。